AccScience Publishing / EJMO / Online First / DOI: 10.36922/EJMO026330420
Cite this article
1
Download
7
Views
Related Info Links
More by Authors Links
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Predictors of survival after transarterial radioembolization in patients with hepatocellular carcinoma

Brian Irving Carr1* ,  Harika Gozukara Bag2 ,  Kutlu Ramazan1,3 ,  Ince Volkan1 ,  Yilmaz Sezai1
Show Less
1 Liver Transplant Institute, Faculty of Medicine, Inonu University, Malatya, Malatya Province , Turkey
2 Department of Biostatistics, Faculty of Medicine, Inonu University, Malatya, Malatya Province , Turkey
3 Department of Radiology, Faculty of Medicine, Inonu University, Malatya, Malatya Province , Turkey
Received: 10 August 2026 | Revised: 14 September 2026 | Accepted: 28 September 2026 | Published online: 16 November 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Introduction: Transarterial radioembolization with yttrium-90–based microspheres (TARE) is an established therapy for patients with advanced non-metastatic hepatocellular carcinoma (HCC). However, factors associated with short or long survival are not completely clear.

Objectives: To examine a cohort of patients not candidates for surgery who were treated with TARE and had known survival duration to document and compare the characteristics of those with shorter versus longer survival times.

Methods: HCC patients (n = 308) were treated exclusively with TARE and followed until death. Their baseline and follow-up blood clinical parameters were retrospectively analyzed. Patients were categorized into short-term (<11 months) and long-term (>11 months) survivors according to the cohort median survival.

Results: The longer- and shorter-survival groups differed significantly in maximum tumor diameter (MTD), multifocality, portal vein thrombosis (PVT), albumin-bilirubin (ALBI), modified ALBI, platelet-ALBI grades, alpha-fetoprotein (AFP), albumin, liver function parameters, and C-reactive protein. In multivariable logistic regression, MTD, multifocality, AFP, albumin, and hemoglobin had significant odds ratios. Patients with PVT were represented in both survival groups. In the longer-survival PVT group, multifocality was significantly less frequent, and MTD, platelet-ALBI grade, aspartate aminotransferase, gamma-glutamyl transferase, and C-reactive protein were lower, while albumin was higher. Increased albumin post-TARE was significantly associated with increased survival, independent of baseline AFP. Patients with normal bilirubin in the total cohort were dichotomized by albumin level. Lower albumin was associated with poorer survival and higher baseline inflammation markers, with no change in tumor factors. Increased albumin or decreased AFP post-TARE were each associated with increased survival.

Conclusion: Baseline tumor and inflammation parameters were independently associated with survival post-TARE, as were increased albumin and decreased AFP in response to TARE.

Keywords
Hepatocellular carcinoma
Radioembolization
Inflammation
Biomarkers
Survival
Funding
This work was supported in part by NIH grant (CA 82723 [BIC]).
Conflict of interest
The authors declare no conflict of interest.
References
  1. Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer. 2010;116(5):1305-1314. doi: 10.1002/cncr.24884
  2. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9(8):1920-1928. doi: 10.1111/j.1600-6143.2009.02695.x
  3. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47(1):71-81. doi: 10.1002/hep.21980
  4. Juthani R, Malalur P, Manne A, Mittra A. The combined use of lenvatinib and locoregional therapies for the management of hepatocellular carcinoma. Cancers (Basel). 2025;17(9):1572. doi: 10.3390/cancers17091572
  5. Garcia-Reyes K, Gottlieb RA, Menon KM, et al. Radioembolization plus immune checkpoint inhibitor therapy compared with radioembolization plus tyrosine kinase inhibitor therapy for the treatment of hepatocellular carcinoma. J Vasc Interv Radiol. 2024;35(5):722-730.e1. doi: 10.1016/j.jvir.2024.02.004
  6. Yu Q, Wang Y, Ungchusri E, et al. Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: a preliminary report of safety and feasibility. J Interv Med. 2023;6(4):187-193. doi: 10.1016/j.jimed.2023.09.002
  7. Gordon AC, Gabr A, Riaz A, et al. Radioembolization super survivors: extended survival in non-operative hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2018;41(10):1557-1565. doi: 10.1007/s00270-018-2008-y
  8. Aujay G, Etchegaray C, Blanc JF, et al. Comparison of MRI-based response criteria and radiomics for the prediction of early response to transarterial radioembolization in patients with hepatocellular carcinoma. Diagn Interv Imaging. 2022;103(7-8):360-366. doi: 10.1016/j.diii.2022.01.009
  9. Makary MS, Bozer J, Miller ED, Diaz DA, Rikabi A. Long-term clinical outcomes of yttrium-90 transarterial radioembolization for hepatocellular carcinoma: a 5-year institutional experience. Acad Radiol. 2024;31(5):1828-1835. doi: 10.1016/j.acra.2023.07.007
  10. Abouchaleh N, Gabr A, Ali R, et al. 90Y radioembolization for locally advanced hepatocellular carcinoma with portal vein thrombosis: long-term outcomes in a 185-patient cohort. J Nucl Med. 2018;59(7):1042-1048. doi: 10.2967/jnumed.117.199752
  11. de Alcântara JPTL, Götz GWXDR. Transarterial radioembolization with yttrium-90 and SIRT versus conventional transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. Acad Radiol. 2025;32(11):6739-6750. doi: 10.1016/j.acra.2025.06.008
  12. Aliseda D, Martí-Cruchaga P, Zozaya G, et al. Liver resection and transplantation following yttrium-90 radioembolization for primary malignant liver tumors: a 15-year single-center experience. Cancers (Basel). 2023;15(3):733. doi: 10.3390/cancers15030733
  13. Tzedakis S, Sebai A, Jeddou H, et al. Resection postradioembolization in patients with single large hepatocellular carcinoma. Ann Surg. 2023;278(5):756-762. doi: 10.1097/SLA.0000000000006061
  14. Gabr A, Kulik L, Mouli S, et al. Liver transplantation following yttrium-90 radioembolization: 15-year experience in 207-patient cohort. Hepatology. 2021;73(3):998-1010. doi: 10.1002/hep.31318
  15. Miller FH, Lopes Vendrami C, Gabr A, et al. Evolution of radioembolization in treatment of hepatocellular carcinoma: a pictorial review. Radiographics. 2021;41(6):1802-1818. doi: 10.1148/rg.2021210014
  16. Carr BI, Bag HG, Kutlu R, Karabulut E, Ince V, Yilmaz S. Prognostic factor and serum biomarker changes in non-surgical hepatocellular carcinoma patients treated with radioembolization. Jpn J Gastroenterol Hepatol. 2026;11(1):1-11. doi: 10.47829/JJGH.2025.11103
  17. Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI grade. J Clin Oncol. 2015;33(6):550-558. doi: 10.1200/JCO.2014.57.9151
  18. Kuo YH, Wang JH, Hung CH, et al. Albumin-bilirubin grade predicts prognosis of HCC patients with sorafenib use. J Gastroenterol Hepatol. 2017;32(12):1975-1981. doi: 10.1111/jgh.13783
  19. Hiraoka A, Michitaka K, Kumada T, et al. Validation and potential of albumin-bilirubin grade and prognostication in a nationwide survey of 46,681 hepatocellular carcinoma patients in Japan: the need for a more detailed evaluation of hepatic function. Liver Cancer. 2017;6(4):325-336. doi: 10.1159/000479984
  20. Hattenhauer T, Mispelbaum R, Heine A, et al. On-treatment modified Glasgow Prognostic Score (mGPS) in hepatocellular carcinoma treated with atezolizumab and bevacizumab provides prognostic information. Front Immunol. 2025;16:1599143. doi: 10.3389/fimmu.2025.1599143
  21. Kaibori M, Hiraoka A, Iida H, et al. Comparison of the new Neo-Glasgow Prognostic Score based on the albumin-bilirubin grade with currently used nutritional indices for prognostic prediction following surgical resection of hepatocellular carcinoma: a multicenter retrospective study in Japan. Cancers (Basel). 2022;14(9):2091. doi: 10.3390/cancers14092091
  22. Kotsifa E, Machairas N, Angelis A, Nikiteas NI, Dimitroulis D, Sotiropoulos GC. Decoding the prognostic significance and therapeutic implications of inflammation-based scores in hepatocellular carcinoma: a comprehensive review. Cancers (Basel). 2024;16(14):2549. doi: 10.3390/cancers16142549
  23. Carr BI, Akkiz H, Guerra V, et al. C-reactive protein and hepatocellular carcinoma: analysis of its relationships to tumor factors. Clin Pract. 2018;15(Spec Issue):625-634.
  24. Huang X, Peng G, Kong Y, Cao X, Zhou X. The prognostic value of CRP/Alb ratio in predicting overall survival for hepatocellular carcinoma treated with transcatheter intra-arterial therapy combined with molecular-targeted agents and PD-1/PD-L1 inhibitors. J Inflamm Res. 2025;18:203-217. doi: 10.2147/JIR.S483208
  25. Nojiri S, Joh T. Albumin suppresses human hepatocellular carcinoma proliferation and the cell cycle. Int J Mol Sci. 2014;15(3):5163-5174. doi: 10.3390/ijms15035163
  26. Bağırsakçı E, Şahin E, Atabey N, Erdal E, Guerra V, Carr BI. Role of albumin in growth inhibition in hepatocellular carcinoma. Oncology. 2017;93(2):136-142. doi: 10.1159/000471807
  27. Fu X, Yang Y, Zhang D. Molecular mechanism of albumin in suppressing invasion and metastasis of hepatocellular carcinoma. Liver Int. 2022;42(3):696-709. doi: 10.1111/liv.15115
  28. Flamm SL. Key insights and clinical pearls in the identification and management of cirrhosis and its complications. Am J Med. 2024;137(10):929-938. doi: 10.1016/j.amjmed.2024.05.015
  29. Virchow R. Die krankhaften Geschwülste. Vol 1. Berlin, Germany: Verlag von August Hirschwald; 1863.
  30. Antkowiak M, Gabr A, Das A, et al. Prognostic role of albumin, bilirubin, and ALBI scores: analysis of 1000 patients with hepatocellular carcinoma undergoing radioembolization. Cancers (Basel). 2019;11(6):879. doi: 10.3390/cancers11060879
  31. Salem R, Gabr A, Riaz A, et al. Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience. Hepatology. 2018;68(4):1429-1440. doi: 10.1002/hep.29691
  32. Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona Clinic Liver Cancer stages: a European evaluation. Hepatology. 2011;54(3):868-878. doi: 10.1002/hep.24451
  33. Wallace MC, Samuelson S, Khoo T, et al. The MAAPE score in intermediate and advanced hepatocellular carcinoma treated with yttrium-90 resin microsphere radioembolization. J Gastroenterol Hepatol. 2020;35(11):1945-1952. doi: 10.1111/jgh.15008
  34. Lee JS, Lee HA, Jeon MY, et al. Establishment and validation of a risk prediction model in patients with hepatocellular carcinoma treated with transarterial radioembolization. Eur J Gastroenterol Hepatol. 2020;32(6):739-747. doi: 10.1097/MEG.0000000000001585
  35. Mansouri Z, Salimi Y, Hajianfar G, et al. The role of biomarkers and dosimetry parameters in overall and progression free survival prediction for patients treated with personalized 90Y glass microspheres SIRT: a preliminary machine learning study. Eur J Nucl Med Mol Imaging. 2024;51(13):4111-4126. doi: 10.1007/s00259-024-06805-8
Share
Back to top
Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing